GE HealthCare to buy SOFIE Biosciences for $945M from Trilantic
GE HealthCare agreed to acquire SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, from Trilantic North America for $945 million in cash. SOFIE operates 15 CMO sites and already manufactures GE HealthCare's Flyrcado F18 product; it will join the PDx pharmaceutical diagnostics segment on closing, expected in the first half of 2027. GE HealthCare also gains U.S. rights to pipeline tracer FAPI-74.
Why it matters: Radiopharmaceuticals live or die on last-mile logistics, and GE HealthCare is buying the distribution network to clear adoption bottlenecks.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →